Mexidol injection instructions for use intramuscularly. Benefits of Injection

Release form

The solution for intravenous and intramuscular administration is colorless or slightly yellowish, transparent.

1 ml of solution contains:

Active substance: ethylmethylhydroxypyridine succinate 50 mg;

Excipients: sodium metabisulphite - 1 mg, water for injection - up to 1 ml.

Package

10 ampoules of 2 ml

pharmachologic effect

Mexidol® has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effects, increases the body's resistance to stress. The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions(shock, hypoxia and ischemia, impaired cerebral circulation, alcohol intoxication and antipsychotic drugs(neuroleptics).

Mexidol® improves brain metabolism and blood supply to the brain, improves microcirculation and rheological properties blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication with acute pancreatitis.

The mechanism of action of Mexidol® is due to its antihypoxant, antioxidant and membrane-protective action. It inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission. Mexidol® increases the content of dopamine in the brain. It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization cell membranes.

Mexidol® normalizes metabolic processes in the ischemic myocardium, reduces the area of ​​necrosis, restores and improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the area of ​​ischemia, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases antianginal activity of nitropreparations.

Mexidol® contributes to the preservation of retinal ganglion cells and fibers optic nerve with progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics

Suction

With the introduction of Mexidol® in doses of 400-500 mg, Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.

Distribution

After the / m administration, the drug is determined in the blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 hours.

breeding

It is excreted from the body with urine mainly in the glucuron-conjugated form and in small quantities - unchanged.

Indications

• acute disorders of cerebral circulation;
• traumatic brain injury, consequences of traumatic brain injury;
• encephalopathy;
• syndrome vegetative dystonia;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like conditions;
• acute myocardial infarction (from the first day) as part of complex therapy;
• primary open-angle glaucoma of various stages, as part of complex therapy;
• relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication antipsychotics;
• acute purulent-inflammatory processes abdominal cavity(acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications

• increased individual sensitivity to the drug;
• acute disorders of the liver and kidneys.

strictly controlled clinical research the safety of the use of the drug Mexidol® in children, during pregnancy and lactation has not been conducted.

Use during pregnancy and lactation

Strictly controlled clinical studies of the safety of Mexidol® during pregnancy and lactation have not been conducted.

Dosage and administration

V / m or / in (stream or drip). With the infusion method of administration, the drug should be diluted in a 0.9% sodium chloride solution.

Jet Mexidol® is injected slowly over 5-7 minutes, drip - at a rate of 40-60 drops per minute. Maximum daily dose should not exceed 1200 mg.

In acute disorders of cerebral circulation, Mexidol® is used in the first 10-14 days - intravenously, 200-500 mg 2-4 times a day, then 200-250 mg intramuscularly 2-3 times a day for 2 weeks .

In case of traumatic brain injury and the consequences of traumatic brain injury, Mexidol® is used for 10-15 days in / in a drip of 200-500 mg 2-4 times a day.

With dyscirculatory encephalopathy in the decompensation phase, Mexidol® should be administered intravenously in a stream or drip at a dose of 200-500 mg 1-2 times a day for 14 days. Then / m 100 - 250 mg / day for the next 2 weeks.

For course prevention of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.

For mild cognitive impairment in elderly patients and for anxiety disorders, the drug is used intramuscularly at a daily dose of 100-300 mg / day. within 14 - 30 days.

At acute infarction myocardial infarction as part of complex therapy Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic remedies according to indications.

In the first 5 days, in order to achieve the maximum effect, it is desirable to administer the drug intravenously, in the next 9 days Mexidol® can be administered intramuscularly.

Intravenous administration the drug is produced by drip infusion, slowly (to avoid side effects) in 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, slow jet administration of the drug is possible, lasting at least 5 minutes.

The introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6 - 9 mg / kg of body weight per day, a single dose - 2 - 3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single - 250 mg.

With open-angle glaucoma of various stages, as part of complex therapy, Mexidol® is administered intramuscularly at 100-300 mg / day, 1-3 times a day for 14 days.

With alcohol withdrawal syndrome, Mexidol® is administered at a dose of 200-500 mg intravenously drip or intramuscularly 2-3 times a day for 5-7 days.

In acute intoxication with antipsychotics, the drug is administered intravenously at a dose of 200-500 mg / day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and in postoperative period. The administered doses depend on the form and severity of the disease, the prevalence of the process, options clinical course. Cancellation of the drug should be made gradually only after a stable positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, Mexidol® is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly. Light degree severity of necrotizing pancreatitis - 100-200 mg 3 times a day in/in drip (in 0.9% sodium chloride solution) and/m. Average degree severity - 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution). Severe course - at a pulse dosage of 800 mg on the first day, with a double regimen of administration; then 200 - 500 mg 2 times a day with a gradual decrease in the daily dose. Extremely severe course- at an initial dosage of 800 mg / day until persistent relief of manifestations of pancreatogenic shock, after stabilization of the condition, 300-500 mg 2 times a day in / in drip (in 0.9% sodium chloride solution) with a gradual decrease in daily dosage.

Side effects

Antioxidant drug

Active substance

Ethylmethylhydroxypyridine succinate (ethylmethylhydroxypyridine succinate)

Release form, composition and packaging

Film-coated tablets from white to white with a creamy tint, round, biconvex.

Excipients: lactose monohydrate - 97.5 mg, - 25 mg, magnesium stearate - 2.5 mg.

The composition of the film shell: Opadry II white 33G28435 - 7.5 mg (hypromellose - 3 mg, titanium dioxide - 1.875 mg, lactose monohydrate - 1.575 mg, polyethylene glycol (macrogol) - 0.6 mg, triacetin - 0.45 mg).

10 pieces. - cellular contour packings (1) - packs of cardboard.
10 pieces. - cellular contour packings (2) - packs of cardboard.
10 pieces. - cellular contour packings (3) - packs of cardboard.
10 pieces. - cellular contour packings (4) - packs of cardboard.
10 pieces. - cellular contour packings (5) - packs of cardboard.

pharmachologic effect

Mexidol is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics / neuroleptics /).

The mechanism of action of the drug Mexidol is due to its antioxidant, antihypoxant and membrane-protective action. The drug inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, increases its fluidity. Mexidol modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission. Mexidol increases the content in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL.

The anti-stress effect is manifested in the normalization of post-stress behavior, somato-vegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures brain.

Mexidol has a pronounced antitoxic effect in withdrawal syndrome. Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, vegetative functions, and is also able to relieve cognitive impairment caused by long-term use of ethanol and its withdrawal. Under the influence of Mexidol, the effect of tranquilizing, neuroleptic, antidepressant, hypnotic and anticonvulsants, which allows to reduce their doses and reduce side effects.

Mexidol improves functional state ischemic myocardium. In conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintain them. functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Pharmacokinetics

Suction and distribution

Rapidly absorbed when taken orally. C max at doses of 400-500 mg is 3.5-4.0 μg / ml.

It is rapidly distributed in organs and tissues. The average retention time of the drug in the body when taken orally is 4.9-5.2 hours.

Metabolism

Metabolized in the liver by glucuronconjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - is formed in the liver and, with the participation of alkaline phosphatase, breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and is found in the urine for 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuronconjugates.

breeding

T 1 / 2 when taken orally - 2-2.6 hours. Rapidly excreted in the urine, mainly in the form of metabolites and in small quantities - unchanged. Most intensively excreted during the first 4 hours after taking the drug. Urinary excretion rates of unchanged drug and metabolites are subject to individual variability.

Indications

- effects acute disorders cerebral circulation, incl. after transient ischemic attacks, in the phase of subcompensation (as preventive courses);

- mild traumatic brain injury, consequences of traumatic brain injury;

- increased individual sensitivity to the drug.

Due to insufficient knowledge of the action of the drug - childhood, pregnancy, breastfeeding.

Dosage

Inside, 125-250 mg 3 times / day; the maximum daily dose is 800 mg (6 tablets). Duration of treatment - 2-6 weeks; for relief of alcohol withdrawal- 5-7 days. Treatment is stopped gradually, reducing the dose within 2-3 days.

The initial dose is 125-250 mg (1-2 tablets) 1-2 times / day with a gradual increase until therapeutic effect; the maximum daily dose is 800 mg (6 tablets).

The duration of the course of therapy in patients with IHD is at least 1.5-2 months. Repeated courses (on the recommendation of a doctor) are preferably carried out in the spring and autumn periods.

Side effects

It is possible that individual adverse reactions: dyspeptic character, allergic reactions.

Overdose

Overdose may cause drowsiness.

How to take Mexidol correctly?

Mexidol® is a domestic drug that is used in many areas of medicine. For a patient who is first prescribed this medicine, it will be of interest detailed instructions on application which describes:What does Mexidol treat?what effect can be expected from therapy with this medication, how much the nootropic costs, and what analogues can replace it.

The drug contains a working substance - biologically active substance Ethylmethylhydroxypyridine succinate in the amount of 125 mg / tab. or 50 mg per 1 ml for intramuscular injection / infusion administration. The composition also includes stabilizing substances.

Mexidol is a nootropic, antioxidant, antihypoxant, tranquilizer at the same time. In addition, the drug has anticonvulsant, anti-Parkinsonian, anti-stress and vegetotropic properties.

Where is the drug used

Neurology.

• Violations of cerebral circulation are acute (ischemic and hemorrhagic strokes) and chronic.
• Atherosclerotic lesions of the cerebral vessels, encephalopathy (including dyscirculatory).
• Vegetative-vascular dystonia.
• neuroses and anxiety disorders.

Cardiology.

• Acute coronary insufficiency.
• Cardiac ischemia.
• Myocardial infarction.
• cardiac dysfunction.

Narcology.

• Withdrawal syndrome on the background of alcohol intoxication or taking psychotropic medications, etc.

Surgery.

• Complications in the form of peritonitis, acute destructive pancreatitis and other purulent-inflammatory processes in the abdominal cavity.

Ophthalmology.

• Pathological changes in the retina on the background of neuropathy. Open-angle glaucoma.

When else can you take Mexidol: indications for use

The tool can also be used in cases where the body functions with increased load or cognitive impairment is present. For example:

• insomnia;
• memory impairment;
• prolonged stress;
• significant physical exercise in athletes and in persons with hard work;
• the recovery period after a craniocerebral and electrical injury;
• chronic intoxication. With the abuse of alcohol-containing substances, the nootropic reduces the damaging effect of ethanol not only on brain structures, but also on hepatocytes;
• increased mental activity;
• senile dementia (degeneration of the brain in the elderly).

Against the background of taking the drug, resistance to damaging factors increases, and cognitive abilities improve.

How does the drug work

The mechanism of action is fundamentally different from the action of other psychotropic drugs, since it does not bind to receptors. Ethylmethylhydroxypyridine succinate in the body acts as follows:

• suppresses the harmful effects of free radicals, activates superoxide dismutase;
• increases the concentration of polar lipid substances, slows down their peroxidation;
• activates the energy capacity of mitochondria, thereby enhancing metabolic processes in cells;
• prevents platelet aggregation;
• has a positive effect on membrane properties, has a stabilizing effect on membranes;
• normalizes the transmission of impulses in the nervous tissue;
• has a positive effect on lipid metabolism: the level of total cholesterol and LDL decreases, and HDL increases.

Due to the many mechanisms of action, the drug affects the main aspects of pathogenesis. various diseases, it has no significant side effects, but it has the ability to enhance the positive effect of other drugs used in neurology and psychiatry, especially direct receptor agonists.

According to the results of clinical studies, the antihypoxant effect is significantly superior to the effect of taking Piracetam and Pyritinol. The properties of the drug are enhanced by succinate, which, with a lack of oxygen, is oxidized intracellularly.

How to take Mexidol: instructions for use

In what form it is better to take an antioxidant (in injections, systems or tablets), the specialist decides in each case individually. The severity of the condition, the availability of therapy, the extent of the lesion, and the characteristics of the course of the disease are taken into account.

If there are indications for intravenous drip (using the system) administration, then the ampoule is first diluted isotonic saline sodium chloride. The rate of administration is 40 - 60 drops / min.

Intravenously, the drug is injected in a stream slowly, over 5 to 7 minutes. The amount of the drug should not exceed 1200 mg per day.

Dosage:

The dosage varies and ranges from 20 to 500 mg, a multiplicity of 1 to 4 times a day. The duration of the course is determined by the doctor (on average, from 2 weeks to a month). After intravenous intramuscular injections or systems, it is possible to transfer to taking tablets.

The drug has an enhancing effect on psychotropic drugs:

• tranquilizers;
• anticonvulsants;
• sleeping pills;
• antidepressants;
• neuroleptics.

This effect allows you to reduce the dosage of drugs.

Contraindications

• Acute violations of the liver and kidneys;
• pregnancy and breastfeeding;
• childhood;
• allergic reactions.

Side effects

• change in taste sensations;
• dry mouth;
• dyspepsia;
• allergic manifestations.

Cancellation of the drug is not required, unwanted effects stopped without action. To eliminate the metallic taste in the mouth intravenous infusion, you need to reduce the rate of injection.

How much does Mexidol cost: the price of an antioxidant in pharmacies

We present to your attention the average cost of a drug in the pharmacy chain and in online pharmacies in Moscow and St. Petersburg:

Mexidol's analogs

We present to your attention a list of common analogues and their average cost:

• Meksidant from 53 rubles. for 1 amp.;
• Mexiprim from 180 rubles;
• Medomexi from 161 rubles. for 1 amp.;
• Cerecard from 160 rubles. for 5 amp. 5 ml;
• Neurox from 39 rubles. for 1 amp.;
• Mexifin from 157 rubles. for 1 amp.;
• Mexicor from 175 rubles.

For comparison: 1 ampoule of 50 mg 2 ml costs from 52 rubles.

To similar means who have another chemical composition, but are used in the treatment of the same diseases, include:

• Instenon;
• Glycine;
• Cortexin;
• Nootropil;
• Piracetam;
• Armadin;
• Antifront;
• Cavinton.

There are schemes when 2 drugs (not structural analogues!) Are prescribed at the same time. This is quite justified, since the impact is carried out on different mechanisms of pathogenesis.

At simultaneous reception Mexidol and Actovegin drugs are strictly forbidden to be mixed in one syringe.

Original domestic antihypoxant and antioxidant direct action, which optimizes the energy supply of cells and increases the reserve capacity of the body

Mexidol tablets - official * instructions for use

*registered by the Ministry of Health of the Russian Federation (according to grls.rosminzdrav.ru)

Registration number:

Tradename drug:

INN or grouping name: Ethylmethylhydroxypyridine succinate.

Chemical rational name: 2-ethyl-6-methyl-3-hydroxypyridine succinate.

Dosage form:

Compound:

Active substance: ethylmethylhydroxypyridine succinate - 125 mg, Excipients: lactose monohydrate, sodium carboxymethylcellulose (sodium carmellose), magnesium stearate, shell: opadra II white (macrogol (polyethylene glycol), polyvinyl alcohol, talc, titanium dioxide).

Description:
Tablets are round, biconvex, film-coated, from white to white with a creamy tint.

Pharmacotherapeutic group:

ATC code: N07XX

Pharmacological properties:

Pharmacodynamics:

Mexidol ® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with alcohol and antipsychotics (neuroleptics)).
The mechanism of action of Mexidol ® is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, increases its fluidity. Mexidol ® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission. Mexidol increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation.
Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.
The anti-stress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, the restoration of sleep-wake cycles, impaired learning and memory processes, and the reduction of dystrophic and morphological changes in various brain structures. Mexidol ® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, vegetative functions, and is also able to relieve cognitive impairment caused by prolonged use of ethanol and its withdrawal. Under the influence of Mexidol, the action of tranquilizers, neuroleptics, antidepressants, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.
Mexidol ® improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Pharmacokinetics:
Rapidly absorbed when taken orally. The maximum concentration at doses of 400 - 500 mg is 3.5 - 4.0 μg / ml. It is rapidly distributed in organs and tissues. The average retention time of the drug in the body when taken orally is 4.9 - 5.2 hours. It is metabolized in the liver by glucuronconjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and with the participation alkaline phosphatase decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and found in the urine for 1 - 2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates. T 1/2 when taken orally - 2.0 - 2.6 hours. Rapidly excreted in the urine mainly in the form of metabolites and in small quantities - unchanged. Most intensively excreted during the first 4 hours after taking the drug. Urinary excretion rates of unchanged drug and metabolites are subject to individual variability.

Indications for use:

• Consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the subcompensation phase as preventive courses;
• Light traumatic brain injury, consequences of traumatic brain injury;
• Encephalopathies various genesis(dyscirculatory, dysmetabolic, post-traumatic, mixed);
• Syndrome of vegetative dystonia;
• Light cognitive disorders of atherosclerotic genesis;
• Anxiety disorders in neurotic and neurosis-like states;
• Ischemic heart disease as part of complex therapy;
• Relief of the withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-abstinence disorders;
• Conditions after acute intoxication with antipsychotics;
• Asthenic conditions as well as to prevent the development somatic diseases under the influence of extreme factors and loads;
• Impact of extreme (stress) factors.

Contraindications:

Acute hepatic and/or kidney failure, increased individual sensitivity to the drug. Due to insufficient knowledge of the action of the drug - children's age, pregnancy, breastfeeding.

Dosage and administration:

Inside, 125 - 250 mg 3 times a day; the maximum daily dose is 800 mg (6 tablets).
Duration of treatment - 2 - 6 weeks; for the relief of alcohol withdrawal - 5 - 7 days. Treatment is stopped gradually, reducing the dose within 2-3 days.
Initial dose - 125 - 250 mg (1 - 2 tablets) 1 - 2 times a day with a gradual increase to obtain a therapeutic effect; the maximum daily dose is 800 mg (6 tablets).
The duration of the course of therapy in patients ischemic disease heart at least 1.5 - 2 months. Repeated courses (on the recommendation of a doctor), it is desirable to conduct in the spring - autumn periods.

Side effect:

Perhaps the appearance of individual adverse reactions: dyspeptic or dyspeptic nature, allergic reactions.

Interaction with others medicines:
Mexidol is combined with all drugs used to treat somatic diseases. Enhances the effect of benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants and antiparkinsonian drugs. Reduces the toxic effects of ethyl alcohol.

Special instructions:

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially dangerous species activities requiring increased concentration attention and speed of psychomotor reactions.

Overdose:

Overdose may cause drowsiness.

Release form:

Coated tablets, 125 mg. 10 tablets in a blister pack made of PVC film and aluminum foil, or 90 tablets in a food grade plastic jar. 1, 2, 3, 4, 5 blister packs or 1 plastic jar with instructions for use in a cardboard pack. For hospitals. Coated tablets, 125 mg. 450 and 900 tablets in a food grade plastic jar with instructions for use in corrugated cardboard boxes.

Storage conditions:

Store in a dry, dark place at a temperature not exceeding 25 °C. Keep out of the reach of children.

Best before date:

3 years. Do not use after the expiration date indicated on the package.

Leave conditions: On prescription

Manufacturer:

BUT: CJSC "ZiO-Health", 142103, Moscow region, Podolsk, st. Zheleznodorozhnaya d. 2
B: CJSC "ALSI-Pharma", CJSC "ALSI Pharma", 129272, Moscow, Trifonovsky dead end, 3,

Organization receiving claims:
LLC "NPK "Pharmasoft" 115280, Moscow, Avtozavodskaya st., 22

Comments(visible only to specialists verified by the editors of MEDI RU)

Pharmaceutical analogues. group*

* Analogues are not equivalent replacements for each other